The University of Pennsylvania School of Nursing
Ultima Vez Modificado: 13 de diciembre del 2011
Please comment on the Finnish protocol of giving 9 weekly administrations of Herceptin versus the 18 - three-weekly administrations that are currently done in the US.
Kevin Fox, MD, Medical Oncologist at Penn , responds:
The Finnish protocol treated a very small number of women, I believe fewer than 200. All of the other studies treated close to 10000 women with one year of herceptin. Although interesting, the weight of current evidence still favors a year of herceptin due to a larger sample of patients. Studies are being done to evaluate shorter courses of herceptin, but one year of treatment must still be considered standard.
This question and answer was part of the OncoLink Brown Bag Chat. Series, View the Life After Breast Cancer transcript.
Oct 1, 2014 - Trastuzumab (Herceptin) is the best drug treatment for human epidermal growth factor receptor 2-positive breast cancer and should remain the standard of care for that type of tumor, according to new research scheduled for presentation at the annual meetin
May 22, 2015